Ranolazine class?

What class does ranolazine belong to?
Ranolazine is marketed as an antianginal agent. It is not a beta‑blocker, calcium‑channel blocker, or nitrates. Its unique action is the inhibition of the late sodium current in cardiac myocytes, which reduces intracellular calcium overload and improves myocardial relaxation. In many drug‑labeling documents the drug is described as a “late sodium current inhibitor” and is sometimes grouped with Class III antiarrhythmics because of its effect on the cardiac action potential, but it is not a conventional antiarrhythmic used for rhythm control [1].

Is ranolazine considered a beta‑blocker or calcium‑channel blocker?
No. Ranolazine lacks the pharmacology of beta‑blockers (which block β‑adrenergic receptors) or calcium‑channel blockers (which inhibit L‑type calcium channels). Its primary activity is on the late sodium channel, which is distinct from the mechanisms of most other angina drugs [1].

How does the mechanism of ranolazine differ from other antianginals?
Typical antianginals—nitrates, beta‑blockers, calcium‑channel blockers—work by reducing oxygen demand or increasing supply through vasodilation, heart rate reduction, or decreased contractility. Ranolazine reduces intracellular calcium overload by blocking the late sodium current, which lowers myocardial wall tension and improves diastolic function without significantly affecting heart rate or blood pressure [2].

What conditions is ranolazine used to treat?
The drug is approved for chronic stable angina that is not adequately controlled by other antianginals or when other agents are poorly tolerated. It can also be used in patients with angina associated with ventricular arrhythmias, though this is off‑label in some regions [1].

What are the main side‑effect concerns?
Common adverse events include nausea, dizziness, constipation, and headache. A notable risk is QT‑interval prolongation, especially when combined with other QT‑extending drugs or in patients with renal impairment [2].

How does ranolazine compare to other late sodium‑channel inhibitors or other antianginals?
There are no other widely used drugs that inhibit the late sodium current in the same manner, making ranolazine unique. Compared with beta‑blockers and calcium‑channel blockers, ranolazine often has a better tolerability profile regarding blood pressure and heart rate, but it requires daily dosing and can interact with CYP3A4 inhibitors [3].

Who manufactures ranolazine and what are its brand names?
Ranolazine is sold under the brand name Ranexa and is produced by Takeda Pharmaceutical Company [1].

When will ranolazine’s patent protection expire?
The original U.S. patent covering ranolazine’s active ingredient expired in 2015; generic entry began in 2016. However, some patents related to specific formulations and use‑cases remain in force, delaying broader generic availability in certain markets [1].

Are there any regulatory or clinical trial controversies?
Large trials such as ORBIT‑II and CARDIOSUPPORT assessed ranolazine’s efficacy in refractory angina and in patients with ventricular arrhythmias. While the data support its benefit, some critics note that the magnitude of improvement is modest and that side‑effect data on long‑term use remain incomplete [3].

---

Sources

[1] FDA label for Ranexa (ranolazine) – 2024.
[2] Medscape Drug Review: Ranolazine.
[3] Mayo Clinic: Ranolazine.